Baseline characteristics/initial safety in RESPOND: phase 4 study of nusinersen in children with SMA who previously received onasemnogene abeparvovec

C. Proud, J. Parsons, R. Masson,J. Brandsema,R. Finkel,K. Swoboda, E. Finanger,Y. Liu, C. Makepeace, A. Paradis,Z. Berger, J. Wagner, K. Somera-Molina

Neuromuscular Disorders(2022)

引用 0|浏览2
暂无评分
关键词
nusinersen,onasemnogene,characteristics/initial safety
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要